Baker Ellis Asset Management LLC Reduces Holdings in Sanofi (NASDAQ:SNY)

Baker Ellis Asset Management LLC lowered its stake in shares of Sanofi (NASDAQ:SNY - Free Report) by 5.7% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 86,908 shares of the company's stock after selling 5,281 shares during the quarter. Baker Ellis Asset Management LLC's holdings in Sanofi were worth $4,192,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in the stock. Jennison Associates LLC boosted its position in shares of Sanofi by 938.0% in the third quarter. Jennison Associates LLC now owns 1,904,445 shares of the company's stock valued at $109,753,000 after acquiring an additional 1,720,972 shares during the period. Thrivent Financial for Lutherans raised its stake in Sanofi by 28,890.2% in the third quarter. Thrivent Financial for Lutherans now owns 1,429,219 shares of the company's stock valued at $82,366,000 after purchasing an additional 1,424,289 shares in the last quarter. JPMorgan Chase & Co. raised its stake in shares of Sanofi by 20.9% during the third quarter. JPMorgan Chase & Co. now owns 2,310,809 shares of the company's stock worth $133,172,000 after acquiring an additional 399,301 shares in the last quarter. Franklin Resources Inc. raised its stake in shares of Sanofi by 13.1% during the third quarter. Franklin Resources Inc. now owns 3,407,452 shares of the company's stock worth $208,106,000 after acquiring an additional 395,744 shares in the last quarter. Finally, Barclays PLC raised its stake in shares of Sanofi by 107.5% during the third quarter. Barclays PLC now owns 639,772 shares of the company's stock worth $36,869,000 after acquiring an additional 331,445 shares in the last quarter. Institutional investors own 14.04% of the company's stock.

Sanofi Stock Up 0.9 %

Shares of SNY stock traded up $0.47 during mid-day trading on Thursday, reaching $51.98. 2,343,650 shares of the company's stock traded hands, compared to its average volume of 2,539,068. Sanofi has a 12 month low of $45.22 and a 12 month high of $58.97. The company has a market cap of $131.92 billion, a P/E ratio of 26.52, a P/E/G ratio of 1.19 and a beta of 0.57. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The company's 50-day moving average price is $48.61 and its 200-day moving average price is $52.16.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Friday, October 25th. The company reported $1.57 EPS for the quarter, beating analysts' consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The firm had revenue of $13.44 billion for the quarter, compared to analysts' expectations of $16.59 billion. During the same quarter in the previous year, the business posted $2.55 EPS. The company's quarterly revenue was up 12.3% on a year-over-year basis. On average, equities analysts expect that Sanofi will post 3.82 earnings per share for the current fiscal year.

Analyst Ratings Changes

Separately, StockNews.com downgraded shares of Sanofi from a "buy" rating to a "hold" rating in a research note on Thursday, December 12th. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.